Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Biogen Eyes 2020 Aducanumab Filing in Japan Too, Nailing Down Re-Dosing Study Details
December 19, 2019
- Jardiance Delivers Favorable Data in Asian RWD Analysis: Boehringer/Lilly
December 19, 2019
- Daiichi Sankyo Aims to Become Global Leader of ADCs: CEO
December 18, 2019
- Chugai Names EVP Okuda as New President
December 18, 2019
- Xtandi Bags Label Expansion in US for Metastatic Castration-Sensitive Prostate Cancer: Astellas/Pfizer
December 18, 2019
- Meiji Pharma Begins PI for Stelara Biosimilar in Europe
December 17, 2019
- Astellas Launches Tender Offer for Audentes
December 17, 2019
- Rohto to Initiate Japan PI of JAK Inhibitor in Ophthalmology Field Later This Month
December 17, 2019
- Sumitomo Dainippon Pulls Plug on SanBio’s Lead Cell Therapy
December 16, 2019
- Asahi Kasei Launches Tender Offer for Veloxis
December 16, 2019
- UMN to Become Shionogi’s Subsidiary on Dec. 19
December 16, 2019
- Nippon Zoki Files Twice-Daily Tramadol Sustained-Release Tab. for Chronic Pain
December 16, 2019
- Boehringer Files Ofev in Japan for Progressive Fibrosing Interstitial Lung Disease
December 16, 2019
- 2 Generic Makers List Fosrenol OD Copies after a Legal Win
December 13, 2019
- Keytruda on Track to Become a US$10 Billion Drug in 2019
December 13, 2019
- Lilly Japan Taps Robot to Prod Participation of Children in Clinical Trials
December 13, 2019
- Mulpleta Gets UK’s NICE OK for Thrombocytopenia: Shionogi
December 13, 2019
- Oncolys to Receive 500 Million Yen from Chugai in Telomelysin Milestone
December 13, 2019
- DS-8201 Achieves ORR of 60.9% in Global PII in HER2-Positive Breast Cancer: Daiichi Sankyo/AZ
December 13, 2019
- AnGes Acquiring 30%-Plus Stake in US Genome Editing Biopharma
December 13, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…